Article

August 17, 2012

Survey: Few ACOs Ready For Financial Risk

Few hospitals interested in becoming accountable care organizations are ready to take on financial risk, according to a survey released Friday from The Commonwealth Fund.

“We’re really still at the very beginning of the adoption curve of the ACO model,” says lead author Anne-Marie Audet, who researches health system quality and efficiency at Commonwealth. “The challenge is that hospitals are still not ready to assume financial risk.”

Read the full story: http://tinyurl.com/8g89z59

Source: Kaiser Health News

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Hadar Avihai Lev-Tov, MD

4 experts in this video

4 experts in this video

Ayodeji Adegunsoye, MD, PhD, MSc

David J. Maron, MD, FASPC, Stanford University School of Medicine

Hadar Avihai Lev-Tov, MD

Senator Vincent Polistina (R, New Jersey)

Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions

Related Content

PFAS | Image credit: Vodkaz - stock.adobe.com

July 29th 2025

PFAS Exposure Linked to Increased Risk of Type 2 Diabetes, Study Finds

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

The Center for Biosimilars podcast banner

July 29th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo

Elena Fenster | Background Image Credit: ipopba - stock.adobe.com

July 29th 2025

Contributor: Reframing Health Literacy—A Systemic Driver of Equity and Outcomes

Improving health literacy is essential for promoting health equity, reducing preventable illness, and making health care more effective.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

July 29th 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

Related Content

PFAS | Image credit: Vodkaz - stock.adobe.com

July 29th 2025

PFAS Exposure Linked to Increased Risk of Type 2 Diabetes, Study Finds

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

The Center for Biosimilars podcast banner

July 29th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo

Elena Fenster | Background Image Credit: ipopba - stock.adobe.com

July 29th 2025

Contributor: Reframing Health Literacy—A Systemic Driver of Equity and Outcomes

Improving health literacy is essential for promoting health equity, reducing preventable illness, and making health care more effective.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

July 29th 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions